Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Using the drugs currently prescribed for schizophrenia or bipolar disorder ... companions about Merck’s development of Crixivan, the anti-HIV drug. “I was hearing a piece of history ...

1st new class of schizophrenia drug in more than 3 decades In September, the FDA approved the first new class of drug to treat people with schizophrenia in more than 30 years. The pill ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic ... Karuna’s New Drug Application ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has ...

27. 2. Cobenfy (xanomeline / trospium chloride) for schizophrenia: Approved Sept. 26, the oral medication targets muscarinic receptors in the brain, differing from other schizophrenia drugs that ...

An antipsychotic medication often prescribed to people with schizophrenia or bipolar is in short supply. Pharmacists and doctors have told the ABC they were not made aware of supply issues until ...